SEARCH:   Advanced

Blood, 15 December 2007, Vol. 110, No. 13, pp. 4614-4617. Prepublished online as a Blood First Edition Paper on September 19, 2007; DOI 10.1182/blood-2007-04-082990. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2007-04-082990v1 110/13/4614    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Olavarria, E. Articles by Craddock, C. F. Search for Related Content PubMed PubMed Citation Articles by Olavarria, E. Articles by Craddock, C. F. Related Collections Transplantation Immunotherapy Brief Reports Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  TRANSPLANTATION Brief Report Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia Eduardo Olavarria1, Shamyla Siddique2, Michael J. Griffiths3, Sharon Avery1, Jenny L. Byrne4, Karen P. Piper2, Anne L. Lennard5, Lalit Pallan2, Julie M. Arrazi2, Jolanta B. Perz1, Derville O'Shea1, John M. Goldman1, Jane F. Apperley1, and Charles F. Craddock6 1 Department of Haematology, Imperial College, Hammersmith Hospital, London; 2 Cancer Research UK (CRUK) Institute for Cancer Studies, University of Birmingham, Birmingham; 3 West Midlands Regional Genetics Laboratory, Birmingham Womens' Hospital, Birmingham; 4 Department of Haematology, Nottingham City Hospital, Nottingham; 5 Department of Haematology, Newcastle Royal Infirmary, Newcastle; and 6 Department of Haematology, Queen Elizabeth Hospital, Birmingham, United Kingdom Disease relapse is a major cause of treatment failure after reduced-intensity allografts and while donor lymphocyte infusions (DLIs) can be effective salvage therapy they are associated with severe graft-versus-host disease (GVHD) when administered early after transplantation. We have therefore examined whether imatinib mesylate can delay relapse and postpone the requirement for DLI in 22 patients with chronic myeloid leukemia (CML) allografted using a reduced-intensity regimen. Imatinib was commenced on day + 35 and continued until 1 year after transplantation. Posttransplantation imatinib was well tolerated and abolished the risk of relapse during this period. Twenty-one patients completed 11 months of imatinib therapy, 15 of whom subsequently relapsed and received DLI. Ten patients to date have achieved molecular remission after DLI. Adjunctive targeted therapy allows the kinetics of disease relapse after a reduced-intensity allograft to be manipulated and represents a novel strategy by which outcome may be improved in patients who undergo transplantation for CML and other leukemias. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: N. B. Heaney, M. Copland, K. Stewart, J. Godden, A. N. Parker, I. G. McQuaker, G. M. Smith, C. Crawley, P. Shepherd, and T. L. Holyoake Complete molecular responses are achieved after reduced intensity stem cell transplantation and donor lymphocyte infusion in chronic myeloid leukemia Blood, May 15, 2008; 111(10): 5252 - 5255. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020